StackTerminal.Health

BETA
Research compound

This compound is primarily studied in research/clinical settings & may not be widely available as a regulated over-the-counter supplement. Information is provided for educational purposes only — not as a recommendation to use. See our Safety page.

Afamelanotide (Melanotan I)

Afamelanotide is a linear MC1R-selective alpha-MSH analogue approved for photoprotection in individuals with erythropoietic protoporphyria, reducing pain and increasing tolerance to sunlight.

photoprotectionpigmentationpainskin-health
Evidence last reviewed: 19 Apr 2026
Supplement note
Private note on this supplement

Save how you reacted, what dose worked, what to watch for, or anything you want to remember later in your Notes tab.

Sign in to keep a private note on Afamelanotide (Melanotan I).
Evidence
3 records
Pain reduction
Individuals with erythropoietic protoporphyriaRCT
PUBMEDModerate

The treatment led to a significant reduction in pain during light exposure.

Dose: 16 mgDuration: Several monthsForm: Subcutaneous Implant
Pain reduction is a secondary benefit of increased photoprotection.
Pigmentation
General populationRCT
PUBMEDModerate

Afamelanotide increased skin pigmentation, which may contribute to photoprotection.

Dose: 16 mgDuration: Several monthsForm: Subcutaneous Implant
Increased pigmentation is a known effect of alpha-MSH analogues.
Photoprotection
Individuals with erythropoietic protoporphyriaRCT
PUBMEDModerate

Afamelanotide significantly increased tolerance to sunlight and reduced pain associated with light exposure.

Dose: 16 mgDuration: Several monthsForm: Subcutaneous Implant
EMA-approved for this indication.
Forms
Subcutaneous Implant
Administered as a slow-release implant for long-term photoprotection.

Stacks containing Afamelanotide (Melanotan I)

Public community stacks that include this ingredient.

Explore all stacks →
No public stacks include this ingredient yet.